Fig. 6
From: Insights into APC/C: from cellular function to diseases and therapeutics
APC/C in tumorigenesis and drug development. Currently, Cdc20 has been recognized as tumor enhancer, whereas Cdh1 has been recognized as tumor suppressor in most type of cancer. Developing specific APC/C inhibitors are potential therapeutic target for cancer treatment. Two inhibitors have been developed, the pro-TAME disrupt APC3-Cdc20 IR-tail binding and Apcin inhibit the D-box binding between Cdc20 and the substrate. The pro-TAME and Apcin have synergistic blockade of mitotic exit effect due to different APC/C activity disrupt mechanism